Physician profile
Kenneth E Misch
NPI 1902886385
$2,411.97
in general payments reported to CMS, 2019-2025
24 companies · $372 in 2025
The $372 reported for 2025 was more than what 89% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $282 · 2020: $202 · 2021: $813 · 2022: $308 · 2023: $173 · 2024: $262 · 2025: $372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $808.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $807.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $410.83 | 2019-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Medline Industries Lp | $360.64 | 2021 | |
| Glaxosmithkline, LLC. | $323.45 | 2019-2025 | Bexsero, Penmenvy, Pediarix |
| Supernus Pharmaceuticals, INC. | $297.79 | 2021-2023 | Qelbree |
| Sanofi-Aventis U.S. LLC | $148.28 | 2024-2025 | |
| Sanofi Pasteur INC. | $143.05 | 2019-2025 | |
| Pfizer INC. | $100.94 | 2021-2025 | |
| Kaleo, INC. | $94.47 | 2021-2022 | |
| Seqirus USA INC | $92.65 | 2022-2025 | Flucelvax, Flucelvax Quadrivalent |
| Neos Therapeutics, Lp | $78.25 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.96 | 2020 | |
| Vertical Pharmaceuticals, LLC | $42.94 | 2019 | |
| Corium, LLC | $42.35 | 2024 | Azstarys |
| Verrica Pharmaceuticals INC. | $36.75 | 2025 | Ycanth |
| Shire North American Group INC | $33.12 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $28.19 | 2024-2025 | Immunocap |
| Ironshore Pharmaceuticals INC. | $25.57 | 2019 | |
| Tris Pharma INC | $19.87 | 2019 | |
| Alexion Pharmaceuticals, INC. | $18.07 | 2019 | |
| Cranial Technologies, INC | $16.43 | 2022 | |
| Acadia Pharmaceuticals INC | $14.53 | 2025 | Daybue |
| Biogen, INC. | $13.67 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $13.54 | 2021 | |
| Boston Scientific Corporation | $11.63 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Misch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.